Solara Active Pharma Sciences Ratios

Solara Active Pharma Sciences Ltd Ratios

The Solara Active Pharma Sciences Ltd Ratios page provides a complete fundamental analysis of Solara Active Pharma Sciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Solara Active Pharma Sciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Solara Active Pharma Sciences Ltd (NSE: SOLARA, BSE: 541540) is currently trading at ₹425.55, with a market capitalization of ₹20.48B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Solara Active Pharma Sciences Ltd remains a key stock for fundamental analysis using Solara Active Pharma Sciences Ltd Ratios.

Solara Active Pharma Sciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Solara Active Pharma Sciences Ltd P/E ratio currently stands at 3790, making it one of the most tracked metrics in Solara Active Pharma Sciences Ltd Ratios.

Historically, the Solara Active Pharma Sciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 3790
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 21.61

The rising Solara Active Pharma Sciences Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Solara Active Pharma Sciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.25.

Historical P/B trend:

• 2024: 2.25
• 2023: 1.44
• 2022: 0.79
• 2021: 1.57

Solara Active Pharma Sciences Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Solara Active Pharma Sciences Ltd P/S ratio currently stands at 1.61, an important part of Solara Active Pharma Sciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.61
• 2023: 1.05
• 2022: 0.83
• 2021: 1.89

The rising Solara Active Pharma Sciences Ltd P/S ratio indicates improved revenue valuation by investors.

Solara Active Pharma Sciences Ltd Price to Cash Flow Ratio (P/CF)

The Solara Active Pharma Sciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 20.36.

Historical Solara Active Pharma Sciences Ltd Price to Cash Flow Ratio:

• 2024: 20.36
• 2023: 142.17
• 2022: 15.52
• 2021: 0
• 2020: 58.43

The declining Solara Active Pharma Sciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Solara Active Pharma Sciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Solara Active Pharma Sciences Ltd EV currently stands at ₹28.4B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 28.4B
• 2023: 23.46B
• 2022: 21.88B
• 2021: 33.83B

Solara Active Pharma Sciences Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Solara Active Pharma Sciences Ltd EV/EBITDA ratio is currently 14.74, a key metric in Solara Active Pharma Sciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 14.74
• 2023: 0
• 2022: 18.37
• 2021: 43.17

Higher Solara Active Pharma Sciences Ltd EV/EBITDA suggests premium valuation.

Solara Active Pharma Sciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Solara Active Pharma Sciences Ltd D/E ratio is currently 0.73, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.73
• 2023: 1.08
• 2022: 0.68
• 2021: 0.68

Solara Active Pharma Sciences Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Solara Active Pharma Sciences Ltd ROE currently stands at 0.05%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 0.05
• 2023: -46.62
• 2022: -1.47
• 2021: -3.74

Declining ROE indicates pressure on profitability.

Solara Active Pharma Sciences Ltd Ratios Analysis Summary

The Solara Active Pharma Sciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Solara Active Pharma Sciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Solara Active Pharma Sciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.